GSK3B and type 2 diabetes mellitus: GSK‐3 activity and expression are found to be higher in type 2 diabetics.[106] Therefore the inhibition of GSK‐3 in type 2 diabetes patients might be a reasonable target to find pharmaceuticals effective against this condition.[107] Seto and co‐workers[108] previously identified the potent and selective GSK‐3β quinolone inhibitor 59 (Figure 29).